These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10794799)

  • 21. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New strategies for enhancing the immunogenicity of tumors.
    Pardoll DM
    Curr Opin Immunol; 1993 Oct; 5(5):719-25. PubMed ID: 7694593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
    Goyvaerts C; Breckpot K
    J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of vaccines against self-antigens: the p53 paradigm.
    Chada S; Mhashilkar A; Roth JA; Gabrilovich D
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer immunotherapy using gene-modified dendritic cells.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    Curr Gene Ther; 2002 Feb; 2(1):57-78. PubMed ID: 12108974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigen-specific immunotherapy and cancer vaccines.
    Jäger E; Jäger D; Knuth A
    Int J Cancer; 2003 Oct; 106(6):817-20. PubMed ID: 12918057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA-based tumor vaccines.
    Pecher G
    Onkologie; 2002 Dec; 25(6):528-32. PubMed ID: 12566897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modern strategies and capabilities for activation of the immune response against tumor cells.
    Sennikov SV; Khantakova JN; Kulikova EV; Obleukhova IA; Shevchenko JA
    Tumour Biol; 2017 May; 39(5):1010428317698380. PubMed ID: 28513301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dendritic cell-based therapeutic cancer vaccines].
    Rizzo M; Alaniz L; Mazzolini GD
    Medicina (B Aires); 2016; 76(5):307-314. PubMed ID: 27723619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Local Radiation Therapy in Cancer Immunotherapy.
    Demaria S; Golden EB; Formenti SC
    JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell-tumor cell hybrids and immunotherapy: what's next?
    Cathelin D; Nicolas A; Bouchot A; Fraszczak J; Labbé J; Bonnotte B
    Cytotherapy; 2011 Aug; 13(7):774-85. PubMed ID: 21299362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell vaccines for cancer immunotherapy.
    Timmerman JM; Levy R
    Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.